Giant Axonal Neuropathy Market grows at highest pace owing to Gene Therapy

Giant Axonal Neuropathy (GAN) is a rare inherited neurodegenerative disorder characterized by damage to the central and peripheral nervous systems, leading to progressive muscle weakness and sensory deficits. Therapeutic approaches in this market focus primarily on advanced gene therapy products, engineered viral vectors, and personalized RNA-based treatments designed to correct the defective gigaxonin gene.

Giant Axonal Neuropathy Market innovative solutions offer significant advantages over traditional palliative care by addressing the root genetic cause, potentially slowing or reversing disease progression. Ongoing research and development activities, buoyed by growing collaborations between biotech firms and academic institutions, have elevated the market scope, driven by supportive regulatory incentives and orphan drug designations. Improved vector delivery systems and precision dosing platforms further enhance safety and efficacy profiles, meeting urgent patient needs and expanding treatment access.

The giant axonal neuropathy (GAN) Market is estimated to be valued at USD 126.4 Mn in 2025 and is expected to reach USD 186.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Get more insights on: Giant Axonal Neuropathy Market

Get this Report in Japanese Language: 巨大軸索性神経障害（GAN）市場

Get this Report in Korean Language: 거대축삭신경병증(GAN)시장

Get more related Articles on: Multiple System Atrophy Poised for Growth with Rising Prevalence